Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Vunakizumab combined with glucocorticoid therapy: Vunakizumab is administered subcutaneously at 240 mg at weeks 0, 2, and 4, followed by maintenance dosing every 4 weeks at 240 mg per dose.